Pacira BioSciences, Inc. (PCRX) Q2 FY26 Earnings Call

Revenue increased 6% to $192.4 million; adjusted EBITDA reached approximately $48.7 million in Q2. [17]

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-08-04
Length38 minutes
EPS$0.44
EPS consensus$0.27
Revenue$192.4M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q4 FY25

All PCRX earnings ยท Back to PCRX overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.